Home » Marsha Zhang

Marsha Zhang


Marsha Zhang was a Manager at CBPartners.

Connect with Marsha Zhang


Published Articles

Cell and Gene Therapies: Paving the Commercial Pathways of Tomorrow

While advanced therapies such as cell and gene therapy have disrupted the healthcare industry, there is much that is still unknown – as well the current appetite for such therapies will wane as their approvals become more common, and the budget implications become real. CBPartners' Cell and Gene Therapy Center of Excellence explores the short and long-term commercial outlook for cell and gene therapies.

STRIMVELIS™ – The Proof Is In The Messaging

In an unprecedented move, the UK's National Institute for Health and Care Excellence (NICE) recently recommended NHS funding of GSK's gene therapy STRIMVELIS™ for an ultra-orphan immunodeficiency disorder ADA-SCID1 – also dubbed the “Bubble Baby Syndrome” priced at EUR 594,000. Given NICE’s resistance to such high per-patient therapy costs, CBPartners investigates how GSK was able to defend the value positioning of the STRIMVELIS™ to NICE.